Skip to main content

Therapeutic Partnerships

Pioneering the Future of Cell-Based Therapies

At Trailhead Biosystems, we specialize in creating a variety of human cells for treating diseases like Parkinson’s, Huntington’s, diabetes, and bone marrow failure. Our approach allows us to quickly develop effective ways to control how stem cells change into different types of human cells. This means we can offer a growing range of cell types for various medical needs, doing so more efficiently and at a lower cost.

We’re looking for partners to help bring these cell therapies into real-world use. Our partnerships are based on a model the established API model, focusing on safely and effectively moving these therapies through clinical trials and then to the market. In these partnerships, our role is to make sure we provide high-quality cells throughout the testing and later, when these therapies are used by patients. We seek partners who are skilled in bringing medical products to people, completing the journey from lab to patient care.

Better Cells for Better Clinical Outcomes

Overcoming Limitations of Current Protocols

  • The Trailhead Difference: We’ve revolutionized cell protocol development through machine-enabled discovery, exploring regulatory inputs efficiently, and achieving unparalleled cell purity.
  • HD-DoE Technology: Our use of mathematically calculated experimental designs executed by liquid handling robotics marks a significant leap in cell protocol development.

Empirical, Data-Driven Approach

  • Innovative Software and Robotics: Our proprietary software tools and robotic experiments allow for speed, precision, and scalability.
  • Unbiased Process Determination: We focus on empirical data and unbiased determination of critical process parameters, building all our protocols from scratch.

High-Dimensional Experimentation for Precise Cell Fate Control

We conduct experiments to understand cell fate behavior in response to various input signals, leading to the extraction of specific cell fate induction recipes. This approach allows us to control cell lineages effectively and avoid conflicting inputs that drive alternative fates.

Introducing the ‘ACI’ Model: A New Era in Cell-Based Therapy

Quality & Scalability

Trailhead’s cells for cell therapies are not only high-quality but also scalable for industrial production. Our proprietary platform empowers our scientists to swiftly identify and develop differentiation protocols for any cell type, including those that are novel or challenging to work with.

Unique Differentiation Protocols

We offer a significant competitive advantage in creating cell therapies for a multitude of diseases and unmet medical needs. Our innovative approach is tailored to address specific conditions effectively.

Cell Therapy Product Portfolio

hiPSC-derived Dopaminergic Neurons

Targeting Parkinson’s Disease: Our hiPSC-derived dopaminergic neurons are specifically tailored for Parkinson’s Disease treatment. Developed using a novel in-house differentiation protocol, these cells have been thoroughly characterized through molecular and cellular assays, ensuring their efficacy and safety.

Unmatched Quality: A key differentiator of our product is the expression of SOX6, a gene critical in distinguishing our dopaminergic neurons from other products in the market. This specificity enhances their therapeutic potential.

Learn More

hiPSC-derived Pancreatic Beta Cells

Battling Type 1 Diabetes: Our hiPSC-derived pancreatic beta cells are a breakthrough in treating Type 1 Diabetes. Developed using a unique differentiation protocol, these cells have demonstrated functionality by producing insulin in response to glucose stimulation.

Innovative Production Process: The production process of these cells is cost-effective and robust, utilizing a method that significantly reduces the production time and increases the yield of insulin-producing cells.

Learn More

Long Term Hematopoietic Stem Cell Medium

Revolutionizing Blood Disorder Treatments: Our long-term hematopoietic stem cell medium is designed to optimize the growth and development of hematopoietic stem cells, potentially transforming treatments for blood disorders and Leukemias.

Cutting-edge Development: This medium was developed by screening an array of compounds using HD-DoE technology. It has shown promising results in preclinical studies, improving engraftment outcomes and showing potential as a transformative therapeutic medium.

Learn More

hiPSC-derived Oligodendrocyte Progenitors

Advancing Neurological Disease Research: These cells are crucial for research and treatment of diseases involving myelin loss, like leukodystrophies. Our technology has streamlined the production of these cells, significantly reducing the differentiation time from traditional methods.

Large-scale Production Capability: Our breakthrough in the production process not only ensures a high-quality batch of cells but also allows for large-scale production. This is pivotal for long-term research and therapeutic applications.

Learn More

Interested in partnering or have a question for us?